EP1812374A1 — Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
Assigned to ADITECH PHARMA AG · Expires 2007-08-01 · 19y expired
What this patent protects
The present invention relates to novel strontium salts of fumaric acid monoalkylesters. The salts are suitable for use as active subtances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders either alone or in combination with anot…
USPTO Abstract
The present invention relates to novel strontium salts of fumaric acid monoalkylesters. The salts are suitable for use as active subtances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders either alone or in combination with another fumaric acid ester.
Drugs covered by this patent
- Vumerity (DIROXIMEL FUMARATE) · Biogen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.